Related Experiment Video
Updated: Mar 21, 2026
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Preventing epileptogenesis: A realistic goal?
Gaetano Terrone1, Alberto Pauletti2, Rosaria Pascente2
1Department of Neroscience, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Department of Translational Medicine, Section of Pediatrics, Federico II University, Napoli, Italy.
Abstract:
The definition of the pathologic process of epileptogenesis has considerably changed over the past few years due to a better knowledge of the dynamics of the associated molecular modifications and to clinical and experimental evidence of progression of the epileptic condition beyond the occurrence of the first seizures. Interference with this chronic process may lead to the development of novel preventive therapies which are still lacking. Notably, epileptogenesis is often associated with comorbid behaviors which are now considered primary outcome measures for novel therapeutics. Anti-epileptogenic interventions may improve not only seizure onset and their frequency and severity but also comorbidities and cell loss, and when applied after the onset of the disease may provide disease-modifying effects by favorably modifying the disease course. In the preclinical arena, several novel targets for anti-epileptogenic and disease-modifying interventions are being characterized and validated in rodent models of epileptogenesis. To move proof-of-concept anti-epileptogenesis studies to validation in preclinical trials and eventually to clinical translation is a challenging task which would be greatly facilitated by the development of non invasive biomarkers of epileptogenesis. Biomarker discovery together with testing potential novel drugs would provide a major advance in the treatment of human epilepsy beyond the pure symptomatic control of seizures.
Insights
Epileptogenesis is a progressive condition, offering new therapeutic targets beyond seizure control. Developing non-invasive biomarkers and disease-modifying treatments is crucial for advancing epilepsy care.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Epileptogenesis is increasingly understood as a dynamic, progressive pathologic process, not just a single event.
- The progression of epilepsy beyond initial seizures highlights the need for therapies targeting the underlying disease course.
- Comorbid behaviors are now recognized as critical outcomes for novel epilepsy therapeutics.
Purpose of the Study:
- To explore novel therapeutic strategies targeting the chronic process of epileptogenesis.
- To investigate anti-epileptogenic interventions for improving seizure control, comorbidities, and cell loss.
- To emphasize the need for disease-modifying treatments in epilepsy.
Main Methods:
- Characterization and validation of novel anti-epileptogenic targets in preclinical rodent models.
- Exploration of interventions that modify the disease course, even after epilepsy onset.
- Focus on developing non-invasive biomarkers for epileptogenesis.
Main Results:
- Preclinical research is identifying new targets for anti-epileptogenic and disease-modifying interventions.
- Interventions show potential to favorably modify the disease course and reduce cell loss.
- The development of non-invasive biomarkers is identified as a key facilitator for clinical translation.
Conclusions:
- Targeting epileptogenesis offers a pathway to preventive and disease-modifying therapies for epilepsy.
- Non-invasive biomarkers are essential for advancing anti-epileptogenesis research and clinical trials.
- Future advances in epilepsy treatment depend on biomarker discovery and novel drug development beyond symptomatic seizure management.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...